Disease registry for central retinal artery occlusion

Tsuda Satoru0 个研究点目标入组 30 人开始时间: 2020年1月28日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•(1) Age 20 years or older at the time consent was obtained (2) Written consent for joining the study was available (3) The onset of nonarteritic retinal artery occlusio n (central retinal artery occlusion) occurred expec ted to start study drug administration within 3 to 48 hours before joining the study (4) Decimal visual acuity in the included eye better than hand motion and worse than 0.1 in a scree ning test

•(1) Presence of vision-affecting disease in the included eye at risk of progression during the trial, including diabetic retinopathy, retinal detachment, macular disease, or retinitis pigmentosa. However, such patients were included if the primary or other physician deemed inclusion unlikely to affect the safety of the patient.
•(2) History of internal eye surgery (including laser treatment) within 90 days before enrollment
•(3) Patients with less than 0.1 visual acuity
•(4) Patients undergoing unapproved or off-label treatment in other clinical trials (corporate clinical trials, physician-led clinical trials, and extended clinical trials), or advanced medicine and specified clinical research
•(5) Patients with poor control of co-morbidity
•(6) A judgement that inclusion was inappropriate by the primary or other physician for any other reason.

发起方

Tsuda Satoru